Apimeds Pharmaceuticals US files initial beneficial ownership statement for Co-CEO Vin Menon
APUS•Co-CEO Vin Menon disclosed Series A Convertible Preferred Stock underlying 484,775 common shares in an initial ownership filing.
APUS•APUS•APUS•Co-CEO Vin Menon disclosed Series A Convertible Preferred Stock underlying 484,775 common shares in an initial ownership filing.
Apimeds Pharmaceuticals US Co-CEO Vin Menon disclosed Series A Convertible Preferred Stock underlying 484,775 common shares in an initial ownership filing.
